Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol
暂无分享,去创建一个
M. Humbert | R. Barst | D. Badesch | G. Simonneau | O. Sitbon | V. McLaughlin | M. Rainisio | L. Rubin | C. Black | N. Galiè | G. Simonneau | Lewis J. Rubin | R. Barst
[1] R. Barst,et al. Survival with first-line bosentan in patients with primary pulmonary hypertension , 2005, European Respiratory Journal.
[2] D. Badesch,et al. Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1-year follow-up study. , 2003, Chest.
[3] M. Clozel. Effects of bosentan on cellular processes involved in pulmonary arterial hypertension: do they explain the long‐term benefit? , 2003, Annals of medicine.
[4] A. Shillington,et al. Survival in Primary Pulmonary Hypertension: The Impact of Epoprostenol Therapy , 2002, Circulation.
[5] Gilles Garcia,et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. , 2002, Journal of the American College of Cardiology.
[6] Avid,et al. BOSENTAN THERAPY FOR PULMONARY ARTERIAL HYPERTENSION , 2002 .
[7] D. Badesch,et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebocontrolled study , 2001, The Lancet.
[8] Stuart Rich,et al. Continuous Intravenous Epoprostenol for Pulmonary Hypertension Due to the Scleroderma Spectrum of Disease , 2000, Annals of Internal Medicine.
[9] B. Groves,et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. , 1996, The New England journal of medicine.
[10] E H Bergofsky,et al. Survival in Patients with Primary Pulmonary Hypertension: Results from a National Prospective Registry , 1991 .